DUBLIN--(BUSINESS WIRE)--The "Beta Secretase 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Beta Secretase 1 - Pipeline Review, H1 2020 Summary ...

With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-beta peptide produce ...

Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer's Disease INDIANAPOLIS, June 13, 2013 /PRNewswire/ -- Eli Lilly ...

BOSTON - In a major breakthrough, researchers at Massachusetts General Hospital (MGH) have discovered how amyloid beta--the neurotoxin believed to be at the root of Alzheimer's disease (AD)--forms in ...

INDIANAPOLIS, June 13, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being ...

In a recent study published in the journal PLOS Biology, researchers used mouse models to demonstrate that neurons were not the only source of abnormal amyloid β proteins contributing to the pathology ...

Philadelphia, PA, April 2, 2015 - With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting ...

INDIANAPOLIS, June 13, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being ...

A key protein must be cut to create amyloid beta. Groundbreaking work identifies the 'lipid raft' in nerve cells where this process occurs, which could offer new targets for drug therapy. In a major ...